

In the article by Dieckmann et al., entitled “MicroRNA miR-371a-3p – A novel serum biomarker of testicular germ cell tumors: evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid” [Urol Int 2016;97:76–83, DOI: 10.1159/000444303], the following “addendum” needs to be published:

K.P. Dieckmann, M. Spiekermann, and G. Belge hold stock in miRdetect GmbH, Bremen, a biotech company aiming to develop a commercially available laboratory test for measuring microRNAs in body fluids. This company was founded after the submission of this manuscript to *Urologia Internationalis*. M. Spiekermann has been an employee of miRdetect GmbH since May 2016. miRdetect GmbH holds a patent for measurements of microRNAs in body fluids at the limit of detection. No other authors have declared conflicts of interests.